Pfizer's tofacitinib review backburnered for three months

Share this article:

Confirming expectations aired during its second quarter conference call, Pfizer announced Tuesday that the FDA has delayed its review of the experimental rheumatoid arthritis drug tofacitinib. The drug was set for review this month, but Pfizer said in a statement that the Janus kinase, or JAK inhibitor, will now come under agency scrutiny November 21.

The company statement reiterated a point made in the July 21 earnings call – that the additional time is just to review supplemental information Pfizer submitted at the agency's request, and that there were no calls for new or additional studies.

If approved, it would be the first new drug mechanism for the disease in a decade. An FDA advisory panel was lukewarm about the drug, even though it endorsed it in May, unconvinced that tofacitinib showed any significant benefit among patients. Initial studies were for patients who had already been on methotrexate therapy, which reduces inflammation and can slow disease progression. Tofacitinib appeared to provide little advantage among these patients, in terms of progression. The latest batch of data, however, covers patients who have not been on methotrexate therapy. Pfizer said during its July earnings call that the results among this set of patients demonstrates a clear benefit.
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.